Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0RV4P
|
||||
| Former ID |
DNCL002529
|
||||
| Drug Name |
Daratumumab
|
||||
| Drug Type |
Antibody
|
||||
| Indication | Multiple myeloma [ICD9: 203; ICD10:C90] | Approved | [1], [2] | ||
| Company |
Genmab Princeton, NJ
|
||||
| Target and Pathway | |||||
| Target(s) | CD38 | Target Info | [3] | ||
| KEGG Pathway | Nicotinate and nicotinamide metabolism | ||||
| Metabolic pathways | |||||
| Calcium signaling pathway | |||||
| Hematopoietic cell lineage | |||||
| Oxytocin signaling pathway | |||||
| Salivary secretion | |||||
| Pancreatic secretion | |||||
| Epstein-Barr virus infection | |||||
| NetPath Pathway | Leptin Signaling Pathway | ||||
| TCR Signaling Pathway | |||||
| PANTHER Pathway | CCKR signaling map ST | ||||
| WikiPathways | Oxytocin signaling | ||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT02252172) Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma. U.S. National Institutes of Health. | ||||
| REF 2 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7395). | ||||
| REF 3 | Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma. N Engl J Med. 2015 Sep 24;373(13):1207-19. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.